OA11082A - Microorganisms with increased production of clavulanic acid - Google Patents

Microorganisms with increased production of clavulanic acid Download PDF

Info

Publication number
OA11082A
OA11082A OA9900170A OA9900170A OA11082A OA 11082 A OA11082 A OA 11082A OA 9900170 A OA9900170 A OA 9900170A OA 9900170 A OA9900170 A OA 9900170A OA 11082 A OA11082 A OA 11082A
Authority
OA
OAPI
Prior art keywords
dna
clavam
clavulanic acid
clavuligerus
ciaim
Prior art date
Application number
OA9900170A
Other languages
English (en)
Inventor
Barry Barton
John Patrick Griffin
Cecillia Anders
Susan Jensen
Roy Henry Mosher
Ashish Sudhakar Paradkar
Original Assignee
Smithkline Beecham Plc
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Univ Alberta filed Critical Smithkline Beecham Plc
Publication of OA11082A publication Critical patent/OA11082A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA9900170A 1997-02-04 1999-08-04 Microorganisms with increased production of clavulanic acid OA11082A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9702218.0A GB9702218D0 (en) 1997-02-04 1997-02-04 Novel product

Publications (1)

Publication Number Publication Date
OA11082A true OA11082A (en) 2003-03-13

Family

ID=10807030

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900170A OA11082A (en) 1997-02-04 1999-08-04 Microorganisms with increased production of clavulanic acid

Country Status (32)

Country Link
US (5) US6936458B1 (fr)
EP (2) EP0970198B1 (fr)
JP (2) JP4227199B2 (fr)
KR (2) KR100514964B1 (fr)
CN (2) CN1192107C (fr)
AP (1) AP1320A (fr)
AR (2) AR011100A1 (fr)
AT (1) ATE312926T1 (fr)
AU (1) AU735782B2 (fr)
BG (1) BG103704A (fr)
BR (1) BR9807144A (fr)
CA (1) CA2279207A1 (fr)
DE (1) DE69832783T2 (fr)
DZ (1) DZ2413A1 (fr)
EA (1) EA003773B1 (fr)
ES (1) ES2255149T3 (fr)
GB (1) GB9702218D0 (fr)
HU (1) HUP0001048A3 (fr)
ID (1) ID22144A (fr)
IL (1) IL131043A0 (fr)
MA (1) MA24464A1 (fr)
MY (1) MY140928A (fr)
NO (1) NO993758L (fr)
NZ (1) NZ336894A (fr)
OA (1) OA11082A (fr)
PL (1) PL334961A1 (fr)
SK (1) SK105499A3 (fr)
TR (1) TR199901862T2 (fr)
TW (2) TW589377B (fr)
UY (2) UY24874A1 (fr)
WO (1) WO1998033896A2 (fr)
ZA (1) ZA98868B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019959A1 (fr) * 1999-09-16 2001-03-22 The Johns Hopkins University Production amelioree d'acide clavulanique
AU1385701A (en) * 1999-10-22 2001-05-08 Smithkline Beecham Plc Novel compounds
GB0308696D0 (en) * 2003-04-15 2003-05-21 Glaxo Group Ltd New process
EP2589663A1 (fr) 2011-11-04 2013-05-08 LEK Pharmaceuticals d.d. Procédé de production d'acide clavulanique
CN107964522B (zh) * 2018-01-04 2020-12-08 上海交通大学 海洋链霉菌dut11及其抗补体活性应用
KR20220031043A (ko) 2019-07-05 2022-03-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 스트렙토미세스 클라불리게루스

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110165A (en) * 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
YU40452B (en) * 1975-02-07 1986-02-28 Beecham Group Plc Process for the elimination of contaminating impurities from clavulinic acid
GB1585661A (en) 1976-06-08 1981-03-11 Glaxo Lab Ltd Clavam derivatives
JPS589679B2 (ja) 1977-02-24 1983-02-22 武田薬品工業株式会社 抗生物質の製造法
US4202819A (en) 1979-05-04 1980-05-13 Hoffman-La Roche Inc. 2-(3-Alanyl)clavam antibiotic
GB8521516D0 (en) * 1985-08-29 1985-10-02 Beecham Group Plc Compounds
GB9020683D0 (en) 1990-09-22 1990-11-07 Univ Strathclyde Isolation of dna
CA2108113C (fr) * 1993-10-08 2006-12-05 Susan E. Jensen Sequence d'adn codant pour des enzymes de la synthese de l'acide clavulanique

Also Published As

Publication number Publication date
KR20000070723A (ko) 2000-11-25
US20030124690A1 (en) 2003-07-03
EP0970198B1 (fr) 2005-12-14
TW589377B (en) 2004-06-01
US20030022321A1 (en) 2003-01-30
EA199900718A1 (ru) 2000-02-28
BG103704A (en) 2000-05-31
ATE312926T1 (de) 2005-12-15
DE69832783D1 (de) 2006-01-19
CN1696301A (zh) 2005-11-16
AP1320A (en) 2004-10-29
AR011100A1 (es) 2000-08-02
US7344869B2 (en) 2008-03-18
JP4227199B2 (ja) 2009-02-18
CA2279207A1 (fr) 1998-08-06
IL131043A0 (en) 2001-01-28
NO993758D0 (no) 1999-08-03
ID22144A (id) 1999-09-09
UY24874A1 (es) 2001-07-31
WO1998033896A2 (fr) 1998-08-06
KR100514964B1 (ko) 2005-09-15
CN1192107C (zh) 2005-03-09
MA24464A1 (fr) 1998-10-01
AP9901614A0 (en) 1999-09-30
SK105499A3 (en) 2000-05-16
EP0970198A2 (fr) 2000-01-12
JP2001511001A (ja) 2001-08-07
US6936458B1 (en) 2005-08-30
TR199901862T2 (xx) 2000-12-21
US20030166175A1 (en) 2003-09-04
AR018304A2 (es) 2001-11-14
UY25197A1 (es) 1998-11-27
EP1405913A3 (fr) 2004-08-04
DZ2413A1 (fr) 2003-01-04
DE69832783T2 (de) 2006-07-20
TW200307041A (en) 2003-12-01
US20070298470A1 (en) 2007-12-27
EA003773B1 (ru) 2003-08-28
ZA98868B (en) 1999-08-03
CN1251612A (zh) 2000-04-26
NZ336894A (en) 2001-08-31
MY140928A (en) 2010-02-12
JP2009022298A (ja) 2009-02-05
NO993758L (no) 1999-08-03
JP5042186B2 (ja) 2012-10-03
BR9807144A (pt) 2000-01-25
GB9702218D0 (en) 1997-03-26
HUP0001048A3 (en) 2001-09-28
WO1998033896A3 (fr) 1998-11-19
EP1405913A2 (fr) 2004-04-07
ES2255149T3 (es) 2006-06-16
KR20050053794A (ko) 2005-06-08
HUP0001048A2 (hu) 2000-08-28
AU6295398A (en) 1998-08-25
PL334961A1 (en) 2000-03-27
AU735782B2 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
US5070020A (en) Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase
US6696282B2 (en) Fusarium sporotrichioides strains for production of lycopene
JPH09107981A (ja) ホスフィノトリシン耐性遺伝子の使用
JP5042186B2 (ja) 多量のクラブラン酸を産生する微生物
WO2002059322A2 (fr) Compositions et methodes liees a la famille de genes biosynthetiques de la daptomycine
CA2108113C (fr) Sequence d'adn codant pour des enzymes de la synthese de l'acide clavulanique
JP2007289193A (ja) クラバム抗生物質の産生を強化する方法
US6589775B1 (en) DNA sequence encoding enzymes of clavulanic acid biosynthesis
US20040081960A1 (en) Novel process
CZ277599A3 (cs) Mikroorganismy se zvýšenou produkcí kyseliny klavulanové
JPH06105682A (ja) β−ラクタム抗生物質産生促進法および大量のＡＣＶシンテターゼ単離法
US6410293B1 (en) DNA fragments containing biotin biosynthetase gene and use of the same
EP1228218A2 (fr) Nouveaux composes
KR19990074514A (ko) 아미노글라이코사이드계 항생제에 대해 다제내성을지정하는유전자
MXPA99007257A (en) Novel compounds